Showing 2371-2380 of 3039 results for "".
- Tarsus Launches Demodex Blepharitis Treatment Xdemvyhttps://modernod.com/news/tarsis-launches-demodex-blepharitis-treatment-xdemvy/2481792/Tarsus Pharmaceuticals announced that Xdemvy (lotilaner ophthalmic solution 0.25%) is now available at pharmacies nationwide for prescription. The FDA approved Xdemvy on July 24, 2023, for the treatment of Demodex blepharitis. “We are delighted that w
- Bonnie Henderson, MD, Named Interim President and CEO of HelpMeSeehttps://modernod.com/news/bonnie-henderson-md-named-interim-president-and-ceo-of-helpmesee/2481776/Bonnie Henderson, MD, has been named interim president and CEO of global nonprofit HelpMeSee. HelpMeSee provides cataract treatment training using its simulation-based training system with the aim of increasing access to treatment and eradicating cataract blindness. &nbs
- Oculis Announces that OCS-01, First Investigational Eye Drop for Front and Back of the Eye, Met Primary Endpoints in Phase 3 OPTIMIZE Trialhttps://modernod.com/news/oculis-announces-that-ocs-01-first-investigational-eye-drop-for-front-and-back-of-the-eye-met-primary-endpoints-in-phase-3-optimize-trial/2481769/Oculis announced positive topline results from its phase 3 OPTIMIZE trial with OCS-01 eye drops, a novel, once-daily, high concentration, preservative-free, topical Optireach formulation of dexamethasone for the treatment of inflammation and pain following ocular surgery. OPTI
- Kodiak Discontinues Further Development of Tarcocimab After Phase 3 Trial Datahttps://modernod.com/news/kodiak-discontinues-further-development-of-tarcocimab-after-phase-3-trial-data/2481748/Kodiak Sciences has announed it discontinuing further development of tarcocimab tedromer, a novel antibody biopolymer conjugate, being evaluated for wet AMD and DME. The decision comes after the GLEAM and GLIMMER studies failed to meet their primary efficacy endpoints. Th
- Optometry and Vision Science Names New Editor-in-Chiefhttps://modernod.com/news/optometry-and-vision-science-announces-new-editor-in-chief/2481744/The American Academy of Optometry (AAO) announced that David Elliott, PhD, FCOptom, FAAO, is the new editor-in-chief of Optometry and Vision Science (OVS). Mr. Elliott succeeds Michael Twa, OD, PhD, FAAO, who is stepping down from the role after 7 years.
- FDA Accepts DORC’s Orphan-Drug Designation Application for Trypan Blue and Brilliant Blue Ghttps://modernod.com/news/fda-accepts-dorcs-orphan-drug-designation-application-for-trypan-blue-and-brilliant-blue-g/2481740/DORC has has received notification from the FDA that their application for orphan drug designation for a dual combination of Trypan Blue and Brilliant Blue G ophthalmic solutions has been granted. DORC's MembraneBlue-Dual ILM and ERM stain has been used in more than 500,00
- RestoringVision Appoints of Three Directors to its Leadership Teamhttps://modernod.com/news/restoringvision-appoints-of-three-directors-to-its-leadership-team/2481739/Nonprofit RestoringVision announced the appointment of three directors to its leadership team to strengthen its impact in solving the global vision crisis. This follows a year of growth, in which RestoringVision expanded its reach by 48 percent in 2022. In 2023, the organization aims to reac
- Genentech Presents Post-Hoc Clinical and Real-World Data for Vabysmo at ASRShttps://modernod.com/news/genentech-presents-post-hoc-clinical-and-real-world-data-for-vabysmo-at-asrs/2481737/Genentech announced that data from its ophthalmology portfolio will be highlighted in 25 abstracts at the 2023 American Society of Retina Specialists (ASRS) annual meeting, which will be held from July 28-August 1 in Seattle. The data advance the clinical and real-world evidence supporting t
- OcuTerra Completes Enrollment in Phase 2 DR:EAM Trial of Topically Delivered OTT166 in Adults with Diabetic Retinopathyhttps://modernod.com/news/ocuterra-completes-enrollment-in-phase-2-dream-trial-of-topically-delivered-ott166-in-adults-with-diabetic-retinopathy/2481732/OcuTerra Therapeutics announced full enrollment in the company’s phase 2 DR:EAM (Diabetic Retinopathy: Early Active Management) clinical trial evaluating topically delivered OTT166 eye drops in adult patients with moderately severe to severe nonproliferative diabeti
- ASRS: Six Cases of Occlusive Retinal Vasculitis Reported After Injection of Apellis’ GA Drug Syfovrehttps://modernod.com/news/asrs-rare-cases-of-retinal-vasculitis-reported-after-injection-of-apellis-ga-drug-syfovre/2481730/Rare cases of retinal vasculitis have occurred after the first injection of Apellis Pharamceuticals’ recently approved geographic atrophy drug Syfovre (pegcetacoplan injection), according to a notification from the ASRS Research and Safety in Therapeutics (ReST) Committee. The safety concer